Lataste X - Search Results

1

Blood pressure and plasma catecholamines in never-treated parkinsonian patients: effect of a selective D1 agonist (CY 208-243).

Durrieu G, Senard JM, Rascol O, Tran MA, Lataste X, Rascol A, Montastruc JL. Durrieu G, et al. Among authors: lataste x. Neurology. 1990 Apr;40(4):707-9. doi: 10.1212/wnl.40.4.707. Neurology. 1990. PMID: 2320249

2

Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.

Emre M, Rinne UK, Rascol A, Lees A, Agid Y, Lataste X. Emre M, et al. Among authors: lataste x. Mov Disord. 1992;7(3):239-43. doi: 10.1002/mds.870070309. Mov Disord. 1992. PMID: 1535688 Clinical Trial.

3

CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.

Rascol O, Fabre N, Teräväinen H, Poewe W, Lücking C, Rinne U, Dupont E, Hirt D, Hoyer M, Lataste X. Rascol O, et al. Among authors: lataste x. Clin Neuropharmacol. 1990 Aug;13(4):303-11. Clin Neuropharmacol. 1990. PMID: 2208182 Clinical Trial.

4

Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.

Temlett JA, Quinn NP, Jenner PG, Marsden CD, Pourcher E, Bonnet AM, Agid Y, Markstein R, Lataste X. Temlett JA, et al. Among authors: lataste x. Mov Disord. 1989;4(3):261-5. doi: 10.1002/mds.870040307. Mov Disord. 1989. PMID: 2571082

5

Comparative profile of tizanidine in the management of spasticity.

Lataste X, Emre M, Davis C, Groves L. Lataste X, et al. Neurology. 1994 Nov;44(11 Suppl 9):S53-9. Neurology. 1994. PMID: 7970011

6

CQA 206-291 in Parkinson's disease: an acute single escalating dosage study.

Lang AE, Riley DE, Vachon L, Lataste X. Lang AE, et al. Among authors: lataste x. Can J Neurol Sci. 1990 Nov;17(4):416-9. doi: 10.1017/s0317167100030997. Can J Neurol Sci. 1990. PMID: 2276100

7

Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. ICS 205-930 Migraine Study Group.

Ferrari MD, Wilkinson M, Hirt D, Lataste X, Notter M; ICS 205-930 Migraine Study Group. Ferrari MD, et al. Among authors: lataste x. Pain. 1991 Jun;45(3):283-291. doi: 10.1016/0304-3959(91)90052-Y. Pain. 1991. PMID: 1876437 Clinical Trial.

8

The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist.

Temlett JA, Quinn NP, Marsden CD, Lataste X, Jaton AL. Temlett JA, et al. Among authors: lataste x. Clin Neuropharmacol. 1989 Feb;12(1):55-9. doi: 10.1097/00002826-198902000-00007. Clin Neuropharmacol. 1989. PMID: 2565766

9

Isradipine in patients with acute ischaemic cerebral infarction. An overview of the ASCLEPIOS Programme.

Azcona A, Lataste X. Azcona A, et al. Among authors: lataste x. Drugs. 1990;40 Suppl 2:52-7. doi: 10.2165/00003495-199000402-00013. Drugs. 1990. PMID: 2150642 Clinical Trial.

10

The blood-brain barrier in hypoxia.

Lataste X. Lataste X. Int J Sports Med. 1992 Oct;13 Suppl 1:S45-7. doi: 10.1055/s-2007-1024590. Int J Sports Med. 1992. PMID: 1483788 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters